

**Supplementary Table 5: Patient information for Figure 4 C**

		<b>CD</b>	<b>UC</b>
<b>Number Patients</b>		33	49
<b>Number Samples</b>		46	78
<b>Age (Ø, range)</b>		41 (18-71)	47 (19-82)
<b>Female [%]</b>		56.5	52.6
<b>HBI (Ø, range)</b>		5.4 (1-12)	
<b>Mayo c.s. (Ø, range)</b>			2.6 (0-7)
<b>Therapy [%]</b>	<i>Aminosalicylates</i>	24.4	36.4
	<i>Steroids</i>	35.6	54.5
	<i>Immunosuppressants</i>	6.7	0.0
	<i>Anti-TNF antibodies</i>	0.0	0.0
	<i>Vedolizumab</i>	100.0	100.0
	<i>Ustekinumab</i>	0.0	0.0
<b>Disease localization [%]</b>		L1: 18.2	E1: 23.9
		L2: 22.7	E2: 32.4
		L3: 34.1	E3: 43.7
		L4: 0.0	
		L4+: 25.0	